ADARx Pharmaceuticals Inc.

11 articles with ADARx Pharmaceuticals Inc.

• ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic

  1/20/2023

  ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the close of a $46 million Series B-1 financing to advance its drug development pipeline as the Company’s first product enters the clinic.

• ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324

  1/20/2023

  ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of hereditary angioedema (HAE).

• ADARx Pharmaceuticals Expands Leadership Team, Appointing Robert MacLeod, Ph.D. as Chief Scientific Officer

  1/9/2023

  ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, announced the expansion of their leadership team through the appointment of Robert MacLeod, Ph.D. as Chief Scientific Officer.

• ADARx Pharmaceuticals Further Expands Leadership Team, Appointing Feriandas Greblikas, M.D. as VP of Clinical Development

  10/18/2022

  ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, today announced the further expansion of their leadership team and clinical development capabilities through the appointment of Feriandas Greblikas, M.D. as Vice President of Clinical Development.

• ADARx Pharmaceuticals Expands Leadership Team, Appointing Christopher Prentiss as CFO

  9/28/2022

  ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, announced the expansion of their leadership team through the appointment of Christopher Prentiss as Chief Financial Officer.

• ADARx Pharmaceuticals Expands Leadership Team, Appointing Andrew Seacat as Head of Toxicology

  6/7/2022

  ADARx Pharmaceuticals, Inc. announced the expansion of their leadership team and development capabilities through the appointment of Andrew Seacat, Ph.D., Executive Director and Head of Toxicology.

• ADARx Pharmaceuticals Expands Leadership Team

  1/25/2022

  ADARx Pharmaceuticals, Inc. today announced the expansion of their leadership team through the appointment of Christopher D. Claeboe, Ph.D., MBA as VP, CMC and Manufacturing.

• 

  ImmPACT Bio Gains $111M, a New Leader and Positive Trial Results

  1/20/2022

  ImmPACT Bio provided an optimistic update on a Phase I clinical study evaluating its CD19-CD20 bi-specific Chimeric Antigen Receptor T-cell (CAR-T) therapy.

• Dr. Hubert Chen Joins ADARx Pharmaceuticals as Chief Medical Officer

  1/5/2022

  ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, announced the appointment of Hubert C. Chen, M.D. as Chief Medical Officer.

• 

  Money on the Move: September 8 – 14

  9/15/2021

  Ramping up after the Labor Day holiday, funds are flowing fast and free into these life science companies.

• ADARx Raises $75 Million to Advance Growing Pipeline

  9/8/2021

  ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA targeting therapeutics, announced the completion of a $75 million Series B financing to advance its drug development pipeline.